Jean-François Franetich

Jean-François Franetich

Auto-generated profile, based on publicly available information

Jean-François Franetich

Sorbonne Université, INSERM, CNRS, Centre d'Immunologie et des Maladies Infectieuses, CIMI-Paris, Paris, France

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2017 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
MMMatthew B. B. McCall
Matthew B. B. McCall
LWLinda J. Wammes
Linda J. Wammes
MLMarijke C. C. Langenberg
Marijke C. C. Langenberg
GGGeert-Jan van Gemert
Geert-Jan van Gemert
JWJona Walk
Jona Walk
RSRobert W. Sauerwein
Robert W. Sauerwein
Infectivity of P. falciparum sporozoites determines the course of primary malaria infection in human volunteers.

12 February 2004 in Parasitology Research
Verified
Journal Article
Closed access
PDF file
MBMyriam Bodescot
Myriam Bodescot
OSOlivier Silvie
Olivier Silvie
ASAnthony Siau
Anthony Siau
PRPhilippe Refour
Philippe Refour
PPPaco Pino
Paco Pino
MDmazier dominique
mazier dominique

15 February 2024 in International Journal of Antimicrobial Agents
Verified
Journal Article
Open access
NANadia Amanzougaghene
Nadia Amanzougaghene
STShahin Tajeri
Shahin Tajeri
JFJean-François Franetich
Jean-François Franetich
KAKutub Ashraf
Kutub Ashraf
VSValérie Soulard
Valérie Soulard
MDmazier dominique
mazier dominique
The control and elimination of malaria caused by Plasmodium vivax is hampered by the threat of relapsed infection resulting from the activation of dormant hepatic hypnozoites. Currently, only the 8-aminoquinolines, primaquine and tafenoquine, have been approved for the elimination of hypnozoites, although their use is hampered by potential toxicity. Therefore, an alternative radical curative drug that safely eliminates hypnozoites is a pressing need. This study assessed the potential hypnozoiticidal activity of the antibiotic azithromycin, which is thought to exert antimalarial activity by inhibiting prokaryote-like ribosomal translation within the apicoplast, an indispensable organelle. The results show that azithromycin inhibited apicoplast development during liver-stage schizogony in P. vivax and Plasmodium cynomolgi, leading to impaired parasite maturation. More importantly, this study found that azithromycin is likely to impair the hypnozoite's apicoplast, resulting in the loss of this organelle. Subsequently, using a recently developed long-term hepatocyte culture system, this study found that this loss likely induces a delay in the hypnozoite activation rate, and that those parasites that do proceed to schizogony display liver-stage arrest prior to differentiating into hepatic merozoites, thus potentially preventing relapse. Overall, this work provides evidence for the potential use of azithromycin for the radical cure of relapsing malaria, and identifies apicoplast functions as potential drug targets in quiescent hypnozoites.

11 August 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
KAKutub Ashraf
Kutub Ashraf
STShahin Tajeri
Shahin Tajeri
ACARNOLD Christophe-Sebastien
ARNOLD Christophe-Sebastien
NANADIA AMANZOUGAGHENE
NADIA AMANZOUGAGHENE
JFJean-François Franetich
Jean-François Franetich
MDmazier dominique
mazier dominique
Artemisinin-based combination therapies (ACT) are the frontline treatments against malaria worldwide. Recently the use of traditional infusions from Artemisia annua (from which artemisinin is obtained) or A. afra (lacking artemisinin) has been controversially advocated. Such unregulated plant-based remedies are strongly discouraged as they might constitute sub-optimal therapies and promote drug resistance. Here, we conducted the first comparative study of the anti-malarial effects of both plant infusions in vitro against the asexual erythrocytic stages of P. falciparum and the pre-erythrocytic (i. e., liver) stages of various Plasmodium species. Low concentrations of either infusion accounted for significant inhibitory activities across every parasite species and stage studied. We show that these antiplasmodial effects were essentially artemisinin-independent and were additionally monitored by observations of the parasite apicoplast and mitochondrion. In particular, the infusions significantly incapacitated sporozoites, and for P. vivax and P. cynomolgi, disrupted the hypnozoites. This provides the first indication that compounds other than 8-aminoquinolines could be effective antimalarials against relapsing parasites. These observations advocate for further screening to uncover urgently needed novel antimalarial lead compounds.